Literature DB >> 25178435

Distribution of interleukin-10 family cytokines in serum and synovial fluid of patients with inflammatory arthritis reveals different contribution to systemic and joint inflammation.

R Scrivo1, P Conigliaro, V Riccieri, M Di Franco, C Alessandri, A Spadaro, R Perricone, G Valesini.   

Abstract

Evidence exists that interleukin (IL)-10 family cytokines may be involved in the pathogenesis of rheumatoid arthritis (RA). We sought to determine whether or not these cytokines are involved in psoriatic arthritis (PsA). We conducted a prospective study on patients with PsA, RA and osteoarthritis (OA); healthy controls (HC) were also included. We analysed IL-20, IL-24 and IL-19 serum and synovial fluid (SF) levels and change of serum levels following treatment with biological agents. IL-20 serum levels were increased in PsA and RA compared with OA patients and HC and with matched SF levels. IL-24 serum levels in PsA, RA and OA patients were higher than those in HC and also with respect to matched SF in PsA. IL-19 serum levels were higher in HC and OA compared with PsA and RA patients; IL-19 SF levels were higher in PsA and RA compared with OA patients, and in PsA compared with RA patients. PsA and RA patients showed a reduction of IL-19 serum levels after biological treatment. Therefore, IL-19 seems to be involved mainly in the joint inflammation, whereas IL-20 and IL-24 appear to participate mainly in the systemic responses. These findings may further the comprehension of the contribution of these cytokines to the inflammatory response involved in chronic arthritis, as well as to the development of novel therapeutic strategies.
© 2014 British Society for Immunology.

Entities:  

Keywords:  IL-10 family cytokine; inflammatory arthritis; serum; synovial fluid

Mesh:

Substances:

Year:  2015        PMID: 25178435      PMCID: PMC4298407          DOI: 10.1111/cei.12449

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  31 in total

Review 1.  The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29.

Authors:  Scott Commins; John W Steinke; Larry Borish
Journal:  J Allergy Clin Immunol       Date:  2008-04-11       Impact factor: 10.793

2.  Cloning, expression and initial characterization of interleukin-19 (IL-19), a novel homologue of human interleukin-10 (IL-10).

Authors:  G Gallagher; H Dickensheets; J Eskdale; L S Izotova; O V Mirochnitchenko; J D Peat; N Vazquez; S Pestka; R P Donnelly; S V Kotenko
Journal:  Genes Immun       Date:  2000-10       Impact factor: 2.676

3.  Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types.

Authors:  L Dumoutier; C Leemans; D Lejeune; S V Kotenko; J C Renauld
Journal:  J Immunol       Date:  2001-10-01       Impact factor: 5.422

4.  IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha.

Authors:  Yuan-Chun Liao; Wei-Guang Liang; Feng-Wei Chen; Ju-Hui Hsu; Jiann-Jou Yang; Ming-Shi Chang
Journal:  J Immunol       Date:  2002-10-15       Impact factor: 5.422

5.  Interleukin-19 upregulates keratinocyte growth factor and is associated with psoriasis.

Authors:  Hsing-Hui Li; Y-C Lin; P-J Chen; C-H Hsiao; J Y-Y Lee; W-C Chen; T-Y Tzung; J-C Wu; Ming-Shi Chang
Journal:  Br J Dermatol       Date:  2005-09       Impact factor: 9.302

6.  Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol.

Authors:  John Rømer; Erik Hasselager; Peder Lisby Nørby; Torben Steiniche; Jes Thorn Clausen; Knud Kragballe
Journal:  J Invest Dermatol       Date:  2003-12       Impact factor: 8.551

7.  The expression of IL-20 and IL-24 and their shared receptors are increased in rheumatoid arthritis and spondyloarthropathy.

Authors:  Tue Wenzel Kragstrup; Kristian Otkjaer; Christian Holm; Annette Jørgensen; Marianne Hokland; Lars Iversen; Bent Deleuran
Journal:  Cytokine       Date:  2007-12-03       Impact factor: 3.861

8.  Expression of IL-19 and its receptors in RA: potential role for synovial hyperplasia formation.

Authors:  N Sakurai; T Kuroiwa; H Ikeuchi; N Hiramatsu; A Maeshima; Y Kaneko; K Hiromura; Y Nojima
Journal:  Rheumatology (Oxford)       Date:  2008-04-08       Impact factor: 7.580

Review 9.  Update on cytokines in rheumatoid arthritis.

Authors:  Fionula Brennan; Jonathan Beech
Journal:  Curr Opin Rheumatol       Date:  2007-05       Impact factor: 5.006

10.  Expression of IL-20 in synovium and lesional skin of patients with psoriatic arthritis: differential response to alefacept treatment.

Authors:  Maria C Lebre; Christina L Jonckheere; Maarten C Kraan; Arno W R van Kuijk; Jan D Bos; Menno de Rie; Danielle M Gerlag; Paul P Tak
Journal:  Arthritis Res Ther       Date:  2012-09-24       Impact factor: 5.156

View more
  16 in total

1.  Calcitonin gene-related peptide can be selected as a predictive biomarker on progression and prognosis of knee osteoarthritis.

Authors:  Tianhua Dong; Heping Chang; Fei Zhang; Wei Chen; Yanbin Zhu; Tao Wu; Yingze Zhang
Journal:  Int Orthop       Date:  2015-03-28       Impact factor: 3.075

2.  Toll-like receptor 2 and 4 induced interleukin-19 dampens immune reactions and associates inversely with spondyloarthritis disease activity.

Authors:  T W Kragstrup; T Andersen; C Holm; B Schiøttz-Christensen; A G Jurik; M Hvid; B Deleuran
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

3.  A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors.

Authors:  Maria Sole Chimenti; Paola Triggianese; Paola Conigliaro; Marco Tonelli; Gianfranco Gigliucci; Lucia Novelli; Miriam Teoli; Roberto Perricone
Journal:  Clin Rheumatol       Date:  2017-07-31       Impact factor: 2.980

4.  Increased interleukin (IL)-20 and IL-24 target osteoblasts and synovial monocytes in spondyloarthritis.

Authors:  T W Kragstrup; M N Andersen; B Schiøttz-Christensen; A G Jurik; M Hvid; B Deleuran
Journal:  Clin Exp Immunol       Date:  2017-05-02       Impact factor: 4.330

5.  Polymorphisms in STAT-4, IL-10, PSORS1C1, PTPN2 and MIR146A genes are associated differently with prognostic factors in Italian patients affected by rheumatoid arthritis.

Authors:  C Ciccacci; P Conigliaro; C Perricone; S Rufini; P Triggianese; C Politi; G Novelli; R Perricone; P Borgiani
Journal:  Clin Exp Immunol       Date:  2016-08-02       Impact factor: 4.330

6.  Role of IL-24 in NK cell activation and its clinical implication in systemic lupus erythematosus.

Authors:  Yundi Tang; Xiaotong Sun; Yuxuan Wang; Huijie Luan; Ruijun Zhang; Fanlei Hu; Xiaolin Sun; Xia Li; Jianping Guo
Journal:  Clin Rheumatol       Date:  2021-02-03       Impact factor: 2.980

7.  The interleukin-20 receptor axis in early rheumatoid arthritis: novel links between disease-associated autoantibodies and radiographic progression.

Authors:  Tue Wenzel Kragstrup; Stinne Ravn Greisen; Morten Aagaard Nielsen; Christopher Rhodes; Kristian Stengaard-Pedersen; Merete Lund Hetland; Kim Hørslev-Petersen; Peter Junker; Mikkel Østergaard; Malene Hvid; Thomas Vorup-Jensen; William H Robinson; Jeremy Sokolove; Bent Deleuran
Journal:  Arthritis Res Ther       Date:  2016-03-11       Impact factor: 5.156

Review 8.  Exploring the Psoriatic Arthritis Proteome in Search of Novel Biomarkers.

Authors:  Shalini M Mahendran; Vinod Chandran
Journal:  Proteomes       Date:  2018-01-24

9.  Cytokine detection and simultaneous assessment of rheumatoid factor interference in human serum and synovial fluid using high-sensitivity protein arrays on plasmonic gold chips.

Authors:  Manfè Valentina; Fleckner Jan; Nørby Lisby Peder; Zhang Bo; Dai Hongjie; Keller Pernille
Journal:  BMC Biotechnol       Date:  2015-08-13       Impact factor: 2.563

10.  Remission and low disease activity in a cohort of real-life patients with rheumatoid arthritis treated with first-line antitumour necrosis factor.

Authors:  Paola Conigliaro; Maria Sole Chimenti; Paola Triggianese; Eleonora Ballanti; Flavia Sunzini; Iaria Duca; Roberto Perricone
Journal:  J Int Med Res       Date:  2016-09       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.